Protagonist Therapeutics Statistics
Share Statistics
Protagonist Therapeutics has 59.60M shares outstanding. The number of shares has increased by 2.13% in one year.
| Shares Outstanding | 59.60M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.43% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 56.33M |
| Failed to Deliver (FTD) Shares | 60 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 3.28M, so 5.51% of the outstanding shares have been sold short.
| Short Interest | 3.28M |
| Short % of Shares Out | 5.51% |
| Short % of Float | 5.83% |
| Short Ratio (days to cover) | 6.93 |
Valuation Ratios
The PE ratio is -16.49 and the forward PE ratio is -30.19.
| PE Ratio | -16.49 |
| Forward PE | -30.19 |
| PS Ratio | 21.69 |
| Forward PS | 14.7 |
| PB Ratio | 3.87 |
| P/FCF Ratio | -18.37 |
| PEG Ratio | n/a |
Enterprise Valuation
Protagonist Therapeutics Inc. has an Enterprise Value (EV) of 1.12B.
| EV / Earnings | -14.13 |
| EV / Sales | 18.6 |
| EV / EBITDA | -12.35 |
| EV / EBIT | -11.92 |
| EV / FCF | -15.75 |
Financial Position
The company has a current ratio of 16.71, with a Debt / Equity ratio of 0.
| Current Ratio | 16.71 |
| Quick Ratio | 16.71 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.34 |
| Cash Flow / Debt | -61.56 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.23% and return on capital (ROIC) is -27.72%.
| Return on Equity (ROE) | -0.23% |
| Return on Assets (ROA) | -0.22% |
| Return on Capital (ROIC) | -27.72% |
| Revenue Per Employee | 476.19K |
| Profits Per Employee | -626.63K |
| Employee Count | 126 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 95.3% in the last 52 weeks. The beta is 2.16, so Protagonist Therapeutics 's price volatility has been higher than the market average.
| Beta | 2.16 |
| 52-Week Price Change | 95.3% |
| 50-Day Moving Average | 44.44 |
| 200-Day Moving Average | 36.82 |
| Relative Strength Index (RSI) | 40.87 |
| Average Volume (20 Days) | 690.60K |
Income Statement
In the last 12 months, Protagonist Therapeutics had revenue of $60.00M and earned -$78.95M in profits. Earnings per share was $-1.39.
| Revenue | 60.00M |
| Gross Profit | 60.00M |
| Operating Income | -93.65M |
| Net Income | -78.95M |
| EBITDA | -90.34M |
| EBIT | -93.65M |
| Earnings Per Share (EPS) | -1.39 |
Balance Sheet
The company has $186.73M in cash and $1.14M in debt, giving a net cash position of $185.59M.
| Cash & Cash Equivalents | 186.73M |
| Total Debt | 1.14M |
| Net Cash | 185.59M |
| Retained Earnings | -615.71M |
| Total Assets | 603.86M |
| Working Capital | 432.19M |
Cash Flow
In the last 12 months, operating cash flow was -$70.24M and capital expenditures -$609.00K, giving a free cash flow of -$70.84M.
| Operating Cash Flow | -70.24M |
| Capital Expenditures | -609.00K |
| Free Cash Flow | -70.84M |
| FCF Per Share | -1.25 |
Margins
Gross margin is 100%, with operating and profit margins of -156.09% and -131.59%.
| Gross Margin | 100% |
| Operating Margin | -156.09% |
| Pretax Margin | -131.59% |
| Profit Margin | -131.59% |
| EBITDA Margin | -150.57% |
| EBIT Margin | -156.09% |
| FCF Margin | -118.08% |
Dividends & Yields
PTGX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -3.38% |
| FCF Yield | -2.89% |
Analyst Forecast
The average price target for PTGX is $54.5, which is 32.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $54.5 |
| Price Target Difference | 32.4% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Scores
| Altman Z-Score | 21.18 |
| Piotroski F-Score | 6 |